

AMENDMENTS TO THE CLAIMS:

The claim listing below replaces all previous versions and listings of claims in the application.

1. (Withdrawn – Currently Amended) A method of producing a single, discrete ~~non-gelatin film dosage~~, comprising:

- a) forming a non-gelatin polymeric film, ~~with or~~ without active ingredients incorporated therein;
- b) applying a polar liquid carrier to one or more surfaces of the film, ~~said the polar liquid carrier~~ incorporating at least one active ingredient; and
- c) allowing the ~~applied polar~~ liquid carrier to associate and ~~cure~~ applied to at least partially ~~cure~~ and associate with the film, to result in~~[:]~~ the complete absorption of the at least one active ingredient fluid being absorbed within the film, wholly or partially, and forming a homogeneous polymer film product.

2. (Withdrawn) A method according to claim 1, wherein the non-gelatin film produced comprises one or more layers which associate with one another to a lesser or greater degree to form a partially or wholly polymerically homogeneous film.

3. (Withdrawn) A method according to claim 1, wherein the polymeric mass of the film or films is increased marginally or substantially after steps b) or c).

4. (Cancelled)

5. (Withdrawn) A method according to claim 1 whereby one or more polymeric substances are also deposited on the film surface.

6. (Withdrawn – Currently Amended) A method according to claim 1, wherein the at least one active ingredient in the polar liquid carrier is transported ~~onto~~~~or~~ into the film during step c) of claim 1.

7. (Withdrawn – Currently Amended) A method according to claim 2 wherein the at least one active ingredient is selectively transported.

8. (Withdrawn) A method according to claim 1, wherein the non-gelatin film comprises a cellulose ether film.

9. (Withdrawn – Currently Amended) A method according to claim 1, wherein the non-gelatin film comprises one or more of the following polymers:

hydroxypropyl methylcellulose (HPMC),

hydroxy propyl cellulose (HPC),

hydroxy ethyl methyl cellulose (HEMC),

hydroxy ethyl cellulose (HEC),

methyl cellulose (MC),

carboxy methylcellulose (CMC),

ethyl cellulose (EC),

sodium carboxy methylcellulose

and salts and derivatives of all aforesaid.

10. (Withdrawn – Currently Amended) A method according to claim 1, wherein the polar liquid carrier comprises a same or similar polymeric material as to which forms the non-gelatin film.

11. (Withdrawn – Currently Amended) A method according to claim 1, wherein the polar liquid carrier comprises a material which is chemically or physically compatible with the material which forms the non-gelatin film.

12. (Withdrawn – Currently Amended) A method according to claim 1, wherein the at least one active ingredient is transported from the polar liquid carrier [[to]] the film.

13. (Withdrawn – Currently Amended) A method according to claim 1, wherein the at least one active ingredient has a higher affinity for the polar liquid carrier than the film.

14. (Withdrawn – Currently Amended) A method according to claim 1, wherein the film at least one active ingredient has a higher affinity for the film than the polar liquid carrier.

15. (Withdrawn – Currently Amended) A method according to claim 1 [[10]], wherein the polar liquid carrier incorporates 2 or more active ingredients have having the same or differing affinities for the film and the polar liquid carrier.

16. (Currently Amended) A discrete film dosage to be taken orally, internally, or epidermally produced by the method of:

- a) forming a non-gelatin polymeric film without active ingredients incorporated therein;
- b) applying a polar liquid carrier transport medium to one or more surfaces of the film, said the polar liquid carrier transport medium incorporating at least one active ingredient; and
- c) allowing the applied polar liquid carrier to associate and cure transport medium applied to at least partially cure and associate with the film, to result in[[:]] the complete absorption of the at least one active ingredient ~~being absorbed~~ within the film, ~~wholly or partially~~, and forming a homogeneous polymer film product.

17. (Cancelled)

18. (Currently Amended) A discrete film dosage according to claim 16, wherein ~~one or more active ingredients are present in the film and have concentration gradients~~ the at least one active ingredient has a concentration gradient associated with one or more bands or patterns within the film.

19. (Currently Amended) A discrete film dosage according to claim 16, wherein the at least one active ingredient continues to move or be transported within the film after the polar liquid carrier transport medium is allowed to at least partially cure and associate with the film.

20. (Currently Amended) A discrete film dosage according to claim 16, wherein one or more layers of the film associate with one another ~~to a lesser or greater degree~~ to form a level of polymeric homogeneity.

21. (Currently Amended) A discrete film dosage according to claim 16, which wherein the polymer film product is coiled.

22. (Currently Amended) A discrete film dosage according to claim 16, which wherein the polymer film product is folded in a zig-zag formation.

23. (Currently Amended) A pharmaceutical dosage form comprising multi-layers of film formed from films the discrete film dosage according to claim 16.

24. (Currently Amended) A pharmaceutical dosage form according to claim 23, wherein the films are laid together before any polar liquid carrier or transport medium applied has cured or dried.

25. (Currently Amended) A discrete film dosage according to claim 16, wherein the polymer film product is packaged to form a dose unit.

26. (Currently Amended) A sheet of discrete film dosage according to claim 16, wherein the film has a the polar liquid carrier transport medium according to claim 16 is applied to the

~~film it, on one or both sides, and on opposing/adjacent areas or non-opposing or adjacent areas or overlapping areas to form a pattern.~~

27. (Cancelled)

28. (Currently Amended) A pharmaceutical dosage form derived from a discrete film dosage according to claim 16.

29. (Withdrawn – Currently Amended) Use of a discrete film dosage according to claim 16, wherein the polymer film product is placed on the tongue of a human or animal and the at least one active ingredient is ingredients are released in a convenient manner as the polymer film product disintegrates.

30. (Currently Amended) A tablet, powder slug or capsule made from or coated, enrobed or encapsulated with a discrete film dosage according to claim 16.

31. (Currently Amended) A tablet or monolith made from multiple layers of a discrete film dosage according to claim 16.

32. (Currently Amended) A tablet or monolith according to claim 31 [[25]], wherein said tablet or monolith comprises three to forty layers.

33. (Currently Amended) A tablet or monolith according to claim 31 [[25]], wherein said tablet or monolith comprises 8 to 25 layers.

34. (Currently Amended) A tablet or monolith according to claim 31 [[25]], wherein the tablet or monolith comprises 10 to 20 layers.

35. (Currently Amended) A multicellular dosage form made from a discrete film dosage according to claim 16.

36. (Withdrawn – Currently Amended) A method according to claim 10, wherein said the polar liquid carrier comprises a material which is chemically or physically compatible with the material which forms the non-gelatin film, and wherein 2 or more active ingredients have the same or differing affinities for the film and liquid.

37. (Currently Amended) A discrete film dosage according to claim 18, which wherein the polymer film product is coiled.

38. (Currently Amended) A discrete film dosage according to claim 19, which wherein the polymer film product is coiled.

39. (Currently Amended) A discrete film dosage according to claim 20, which wherein the polymer film product is coiled.

40. (Previously Presented) A non-gelatin polymeric film wherein said film comprises two or more bands, at least one active ingredient being dispersed within a particular band, said film being a single film with structural homogeneity between said bands.

41. (New) A discrete film dosage according to claim 16, wherein the polymeric film is initially un-plasticized or partially plasticized, and the applied polar liquid carrier confers a plasticizing effect to the film.

42. (New) A discrete film dosage according to claim 16, wherein the polar liquid carrier comprises a material which is chemically or physically compatible with the non-gelatin polymeric film.

43. (New) A discrete film dosage according to claim 16, wherein the polar liquid carrier is cured at room temperature.

44. (New) A discrete film dosage according to claim 16, wherein the polar liquid carrier is cured through application of heat to a temperature below the boiling point of the polar liquid carrier.

45. (New) A discrete film dosage according to claim 16, wherein the mass of the film is increased after steps b) and c).

46. (New) A discrete film dosage according to claim 16, wherein the non-gelatin polymeric film comprises a cellulose ether film.

47. (New) A discrete film dosage according to claim 16, wherein the non-gelatin polymeric film comprises one or more of the following polymers:

hydroxypropyl methylcellulose (HPMC),

hydroxy propyl cellulose (HPC),

hydroxy ethyl methyl cellulose (HEMC),

hydroxy ethyl cellulose (HEC),

methyl cellulose (MC),

carboxy methylcellulose (CMC),

ethyl cellulose (EC),

sodium carboxy methylcellulose,

and salts and derivatives of all aforesaid.

48. (New) A discrete film dosage according to claim 16, wherein the polymer film product is edible.

49. (New) A discrete film dosage according to claim 16, wherein the polymer film product is muco-adhesive.

50. (New) A discrete film dosage according to claim 16, wherein the polymer film product is a medical device.

51. (New) A discrete film dosage according to claim 16, wherein the at least one active ingredient incorporated in the polar liquid carrier has at least one of a therapeutic effect, an organoleptic effect, a cosmetic effect, and a pharmaceutical effect.

52. (New) A discrete film dosage according to claim 16, wherein the at least one active ingredient incorporated in the polar liquid carrier is a pharmaceutical compound.

53. (New) A pharmaceutical dosage form derived from a discrete film dosage according to claim 16.

54. (New) A discrete film dosage according to claim 16, wherein the at least one active ingredient has a concentration gradient associated with one or more patterns within the polymer film product.

55. (New) A discrete film dosage according to claim 16, wherein the polymer film product can be applied mucosally, orally, or topically.